Evolus Inc (NASDAQ:EOLS) has received an average rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $32.50.

EOLS has been the subject of several recent research reports. Cantor Fitzgerald restated a “buy” rating and set a $35.00 target price on shares of Evolus in a report on Monday, September 17th. Zacks Investment Research cut shares of Evolus from a “hold” rating to a “sell” rating in a report on Tuesday, September 25th.

Shares of EOLS stock traded up $0.22 during trading hours on Friday, hitting $16.18. 267,503 shares of the company were exchanged, compared to its average volume of 430,975. Evolus has a 52 week low of $6.75 and a 52 week high of $39.50. The company has a market capitalization of $444.04 million and a price-to-earnings ratio of -59.93.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Monday, November 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.09). As a group, sell-side analysts predict that Evolus will post -1.84 earnings per share for the current fiscal year.

In other news, Director Kristine Romine purchased 6,347 shares of the business’s stock in a transaction on Thursday, November 29th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $88,858.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Corp Alphaeon sold 573,888 shares of the stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $14.00, for a total transaction of $8,034,432.00. The disclosure for this sale can be found here. In the last quarter, insiders acquired 17,147 shares of company stock valued at $228,880.

A number of hedge funds have recently made changes to their positions in EOLS. Bank of New York Mellon Corp acquired a new stake in shares of Evolus during the 2nd quarter worth about $430,000. SG Americas Securities LLC acquired a new stake in shares of Evolus during the 2nd quarter worth about $108,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Evolus during the 2nd quarter worth about $258,000. BlackRock Inc. lifted its stake in shares of Evolus by 58.7% during the 2nd quarter. BlackRock Inc. now owns 300,509 shares of the company’s stock worth $8,411,000 after buying an additional 111,123 shares during the last quarter. Finally, Raymond James & Associates acquired a new stake in shares of Evolus during the 2nd quarter worth about $327,000. Hedge funds and other institutional investors own 24.40% of the company’s stock.

About Evolus

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Further Reading: Systematic Risk

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.